126 related articles for article (PubMed ID: 11158619)
1. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
Shechter Y; Preciado-Patt L; Schreiber G; Fridkin M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1212-7. PubMed ID: 11158619
[TBL] [Abstract][Full Text] [Related]
2. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
Peleg-Shulman T; Tsubery H; Mironchik M; Fridkin M; Schreiber G; Shechter Y
J Med Chem; 2004 Sep; 47(20):4897-904. PubMed ID: 15369394
[TBL] [Abstract][Full Text] [Related]
3. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.
Gershonov E; Goldwaser I; Fridkin M; Shechter Y
J Med Chem; 2000 Jun; 43(13):2530-7. PubMed ID: 10891112
[TBL] [Abstract][Full Text] [Related]
4. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
5. N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative.
Shechter Y; Tsubery H; Fridkin M
J Med Chem; 2002 Sep; 45(19):4264-70. PubMed ID: 12213067
[TBL] [Abstract][Full Text] [Related]
6. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
Sasson K; Marcus Y; Lev-Goldman V; Rubinraut S; Fridkin M; Shechter Y
J Control Release; 2010 Mar; 142(2):214-20. PubMed ID: 19883707
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.
Pan M; Kalie E; Scaglione BJ; Raveche ES; Schreiber G; Langer JA
Biochemistry; 2008 Nov; 47(46):12018-27. PubMed ID: 18937499
[TBL] [Abstract][Full Text] [Related]
9. [2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.
Shechter Y; Tsubery H; Fridkin M
Biochem Biophys Res Commun; 2003 May; 305(2):386-91. PubMed ID: 12745087
[TBL] [Abstract][Full Text] [Related]
10. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
11. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
[TBL] [Abstract][Full Text] [Related]
12. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.
King M; Kumar P; Michel D; Batta R; Foldvari M
Eur J Pharm Biopharm; 2013 Aug; 84(3):532-9. PubMed ID: 23500117
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
14. Engineered acid-stabile human interferon gamma.
Kontsek P; Waschütza G; Kontseková E; Otto B
Cytokine; 2000 Jun; 12(6):708-10. PubMed ID: 10843749
[TBL] [Abstract][Full Text] [Related]
15. The biological effects of five feline IFN-alpha subtypes.
Baldwin SL; Powell TD; Sellins KS; Radecki SV; Cohen JJ; Milhausen MJ
Vet Immunol Immunopathol; 2004 Jun; 99(3-4):153-67. PubMed ID: 15135982
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
[TBL] [Abstract][Full Text] [Related]
17. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
Yuan L; Wang J; Shen WC
J Control Release; 2008 Jul; 129(1):11-7. PubMed ID: 18448186
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
[TBL] [Abstract][Full Text] [Related]
19. ELISA measurement of interferons.
Garrison TL; Hung F; Izotova L; Schwartz B; Lavoie T; Lee-Own FV
Biotechniques; 2002 Oct; Suppl():98-100. PubMed ID: 12395933
[No Abstract] [Full Text] [Related]
20. Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli.
Ooi EL; Verjan N; Hirono I; Nochi T; Kondo H; Aoki T; Kiyono H; Yuki Y
Fish Shellfish Immunol; 2008 May; 24(5):506-13. PubMed ID: 18329900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
